News & Press Releases

Stent Thrombosis and Bleeding Highest within 30 Days of Procedure; Cobra PzF Stent Shows Promise as Means to Address

San Antonio - September 6 2018 - James Pitt (Dexur)

In Dexur’s national data, there were about 150,000 Percutaneous Cardiovascular Procedures With Coronary Artery Stent each year from 2013-2016 in Medicare-eligible inpatients. Stents are a diverse and fast-moving market. The most common devices are bare-metal or drug-eluting, but innovations like CeloNova’s polymer-coated Cobra PzF stent may have advantages for patients at high risk of bleeding. This advantage comes indirectly, through reducing the risk of stent thrombosis.

Clinical Data for Stenting High-Risk Patients Requiring Short DAPT

San Antonio - July/August 2018 (Cardiac Interventions Today)

Complications from bleeding after percutaneous coronary intervention (PCI) occur more frequently than myocardial infarctions and have a greater impact on mortality.1 Patients at high risk of bleeding and thrombosis have historically been a challenging population to treat due to concerns with the safety of drug-eluting stents (DES) with short dual antiplatelet therapy (DAPT) and the efficacy of bare-metal stents due to higher rates of restenosis.

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

San Antonio - May 23 2018

CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company’s COBRA PzF™ NanoCoated Coronary Stent (NCS) System.

Study to explore shortest-ever duration of triple therapy after PCI

Munich, Germany - April 18 2018 - Roisin Colleran and Adnan Kastrati (Cardiovascular News)

The COBRA REDUCE trial is exploring the safety and efficacy of prescribing dual antiplatelet therapy (DAPT) for just two weeks in high bleeding risk patients who are already receiving oral anticoagulation and who have undergone percutaneous coronary intervention (PCI) with the Cobra PzF stent (Celonova). This represents the shortest duration of triple therapy that has been studied in a randomised controlled trial. Roisin Colleran and Adnan Kastrati review the rationale and aims of the trial.

Browse Our Archives